Tarsus Pharmaceuticals (TARS) Other Non-Current Liabilities (2019 - 2026)

Tarsus Pharmaceuticals' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $16.1 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $16.1 million; the TTM figure through Mar 2026 stood at $16.1 million (changed N/A YoY), while the FY2025 annual figure was $10.6 million, changed N/A from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $16.1 million, up from $10.6 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $16.1 million in Q1 2026, with the low at $40000.0 in Q1 2023.
• The 5-year median for Other Non-Current Liabilities is $1.5 million (2024), against an average of $3.4 million.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities slumped 91.94% in 2023, then jumped 3915.0% in 2024.
• Tarsus Pharmaceuticals' Other Non-Current Liabilities stood at $100000.0 in 2022, then surged by 1648.0% to $1.7 million in 2023, then dropped by 29.06% to $1.2 million in 2024, then soared by 754.76% to $10.6 million in 2025, then jumped by 51.7% to $16.1 million in 2026.
• Business Quant data shows TARS's Other Non-Current Liabilities at $16.1 million in Q1 2026, $10.6 million in Q4 2025, and $10.1 million in Q3 2025.